Denis P, Elena P P
Ophtalmologie. 1989 Jan-Mar;3(1):62-4.
Beta-blockers are widely used in the primary open angle glaucoma treatment. The molecular mechanism by which these drugs reduce intraocular pressure is essentially based on the blockade of beta-adrenergic receptors localized on the ciliary processes. Vascular effects of beta-blockers, which are difficult to exhibit clinically, have been recently reported for some drugs with intrinsic sympathomimetic activity. In this study, we attempted to investigate the presence of beta-adrenergic specific binding sites on the human retinal vessels, by means of an in vitro autoradiographic technique. These receptors are localized both on arteries and veins; displacement studies indicated that they are mainly of beta-2 subtype.
β受体阻滞剂广泛应用于原发性开角型青光眼的治疗。这些药物降低眼压的分子机制主要基于对睫状突上β肾上腺素能受体的阻断。β受体阻滞剂的血管效应在临床上难以表现出来，最近有报道称某些具有内在拟交感活性的药物有此效应。在本研究中，我们试图通过体外放射自显影技术研究人视网膜血管上β肾上腺素能特异性结合位点的存在情况。这些受体定位于动脉和静脉；置换研究表明它们主要是β-2亚型。
